Oral Silodosin on Lower Urinary Tract Symptoms Due to Double-J stent: A Prospectively Randomized Study

Oral silodosin on lower urinary tract symptoms due to double-J stent

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12611000569909

Enrollment

Registered

2011-06-03

Start date

2010-11-01

Completion date

2012-04-30

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

a randomized double-blinded controlled study to evaluate the effect of silodosin in improving symptoms and quality of life in patients with indwelling double-J ureteral stents using specific questionnaire

Interventions

daily oral silodosin 4 mg for 2 weeks in improving symptoms and quality of life in patients with indwelling double-J ureteral stents using specific questionnaire

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Healthy volunteers

Inclusion criteria

patients, with insertion of a double-J ureteral stent after ureteroscopic stone removal, were enrolled into the study

Exclusion criteria

benign prostatic hyperplasia-related lower urinary symptoms(International Prostate Symptom Score greater greater than 7); a history of interstitial cystitis, chronic cystitis, chronic prostatitis, or stent insertion; and chronic medication with alpha-blockers or analgesics

Outcome results